Boston, Massachusetts 02446


Purpose:

Simvastatin will attenutat IL-6 levels and lead to a more rapid shock reversal than placebo


Criteria:

Inclusion Criteria: - Greater than 18 years old - Hypotensive requiring vasopressors - Suspected Infection Exclusion Criteria: - Pregnant - Liver Failure (ALT or AST > 120) - Rhabomyolysis (CPK > 3x normal) - Comfort care measures status - Chronic Liver Disease (Cirrhosis) - Use of Cyclosporin, Digoxin, Statins - Patients who are unable to take medications by mouth or NGT


NCT ID:

NCT00676897


Primary Contact:

Principal Investigator
Michael W Donnino, MD
Beth Israel Deaconess Medical Center


Backup Contact:

N/A


Location Contact:

Boston, Massachusetts 02446
United States

Michael Donnino, MD
Phone: 617-667-7000
Email: mdonnino@bidmc.harvard.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: January 17, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.